On Monday, Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) opened lower -5.36% from the last session, before settling in for the closing price of $17.91. Price fluctuations for CNTA have ranged from $5.58 to $18.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 1.99% at the time writing. With a float of $89.08 million, this company’s outstanding shares have now reached $131.66 million.
In an organization with 76 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 89.52%, operating margin of -2342.65%, and the pretax margin is -2294.59%.
Centessa Pharmaceuticals plc ADR (CNTA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Centessa Pharmaceuticals plc ADR is 32.34%, while institutional ownership is 51.12%. The most recent insider transaction that took place on Nov 25 ’24, was worth 5,451. In this transaction Chief Executive Officer of this company sold 299 shares at a rate of $18.23, taking the stock ownership to the 575,661 shares. Before that another transaction happened on Nov 25 ’24, when Company’s Chief Business Officer sold 10,000 for $17.66, making the entire transaction worth $176,601. This insider now owns 183,266 shares in total.
Centessa Pharmaceuticals plc ADR (CNTA) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.38 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.5) by 0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 1.99% per share during the next fiscal year.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Check out the current performance indicators for Centessa Pharmaceuticals plc ADR (CNTA). In the past quarter, the stock posted a quick ratio of 21.52. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 322.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.55 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.63 million. That was better than the volume of 0.42 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 73.41%. Additionally, its Average True Range was 1.08.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 81.62%, which indicates a significant increase from 52.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.62% in the past 14 days, which was higher than the 61.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.21, while its 200-day Moving Average is $12.09. However, in the short run, Centessa Pharmaceuticals plc ADR’s stock first resistance to watch stands at $17.54. Second resistance stands at $18.13. The third major resistance level sits at $18.44. If the price goes on to break the first support level at $16.64, it is likely to go to the next support level at $16.33. The third support level lies at $15.74 if the price breaches the second support level.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Key Stats
There are currently 131,845K shares outstanding in the company with a market cap of 2.23 billion. Presently, the company’s annual sales total 6,850 K according to its annual income of -151,090 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -42,570 K.
